Compare NXJ & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NXJ | BBNX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 503.5M | 555.7M |
| IPO Year | N/A | N/A |
| Metric | NXJ | BBNX |
|---|---|---|
| Price | $12.47 | $11.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $26.73 |
| AVG Volume (30 Days) | 112.1K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 3.27% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $35.03 |
| Revenue Next Year | N/A | $33.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.01 | $8.89 |
| 52 Week High | $12.90 | $32.71 |
| Indicator | NXJ | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 25.65 |
| Support Level | $11.24 | N/A |
| Resistance Level | $12.76 | $15.53 |
| Average True Range (ATR) | 0.09 | 0.95 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 17.21 | 6.44 |
Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.